2025
SJR Q1
JCR Q1 · 17,5
OA
SCIE
Journal detail
Experimental Hematology and Oncology
- Publisher
- BioMed Central Ltd
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
21623619
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 4,126
- Quartile Q1
- H-Index 58
- Cites/doc 10,49
- Docs (3y) 325
- Cites (3y) 3.240
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 17,5
- 5Y JIF 14,9
- JCI 2,25
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Cancer Research Q1
- Hematology Q1
- Oncology Q1
Areas
- Biochemistry, Genetics and Molecular Biology
- Medicine
WoS categories
- Oncology | Hematology
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 4,126 | 17,5 | 14,9 | 2,25 | Q1 | 58 |
| 2024 | Q1 | Q1 | 3,092 | 13,5 | 11,3 | 1,95 | Q1 | 47 |
| 2023 | Q1 | Q1 | 2,384 | 9,4 | 8,3 | 1,6 | Q1 | 47 |
| 2022 | Q1 | Q1 | 1,908 | 11,4 | 7,3 | 1,46 | Q1 | 47 |
| 2021 | Q1 | Q1 | 1,301 | 8,6 | 5,9 | 1,08 | Q1 | 47 |
| 2020 | Q1 | Q2 | 1,223 | 5,1 | 3,7 | 0,75 | Q2 | 47 |
| 2019 | Q2 | Q2 | 0,941 | 3,5 | — | 0,66 | Q2 | 47 |
| 2017 | Q2 | — | 0,842 | — | — | — | — | 47 |
| 2016 | Q2 | — | 0,992 | — | — | — | — | 47 |
| 2015 | Q2 | — | 0,971 | — | — | — | — | 47 |
| 2014 | Q2 | — | 0,845 | — | — | — | — | 47 |
| 2013 | Q2 | — | 1,197 | — | — | — | — | 47 |
| 2012 | — | — | — | — | — | — | — | 47 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | HEMATOLOGY | SCIE | Q1 | Q1 | 5/103 |
| 2025 | ONCOLOGY | SCIE | Q1 | Q1 | 19/333 |
| 2024 | HEMATOLOGY | SCIE | Q1 | Q1 | 6/99 |
| 2024 | ONCOLOGY | SCIE | Q1 | Q1 | 19/328 |
| 2023 | HEMATOLOGY | SCIE | Q1 | Q1 | 10/97 |
| 2023 | ONCOLOGY | SCIE | Q1 | Q1 | 32/322 |
| 2022 | HEMATOLOGY | SCIE | Q1 | Q1 | 7/79 |
| 2022 | ONCOLOGY | SCIE | Q1 | Q1 | 23/241 |
| 2021 | HEMATOLOGY | SCIE | Q1 | Q1 | 14/78 |
| 2021 | ONCOLOGY | SCIE | Q1 | Q1 | 40/245 |
| 2020 | HEMATOLOGY | SCIE | Q2 | Q2 | 24/76 |
| 2020 | ONCOLOGY | SCIE | Q2 | Q2 | 87/242 |
| 2019 | HEMATOLOGY | SCIE | Q2 | Q2 | 24/76 |
| 2019 | ONCOLOGY | SCIE | Q2 | Q3 | 110/244 |